No abstract

No abstract

Background: Traditionally, paper based suspected ADR forms were the only way of submitting suspected ADR (sADR) data. Recently the mobile android based ADR reporting app© (App©) has also been developed and a copyright was granted to the author. This study is done to assess the two, viz. paper based and App based, methods of submission of sADR data.Methods: The sADR data submitted to the ADR Monitoring Centre (AMC), at Department of Pharmacology, NSCB MC Jabalpur. There is no such scale to assess the completeness of suspected ADR data received by individual AMCs. Therefore, appropriate algorithm and scale for Completeness scoring of filled sADR forms was designed, the basic tenets were adhered. A set of 10 sADR forms, submitted by either method, were subjected to Independent assessment by 3 assessors, who were not part of this study. The scores were then subjected to analysis, which revealed minimal variation across the assessment. Hence, the scale was adopted for the study.Results: A total of 403 sADR’s submitted to our AMC, were screened and subjected to scoring for completeness. Upon screening, 96.2% (257/267) sADR submitted via paper based sADR form and 100% (136/136) of those submitted via App stood valid, and hence included in the study. All the suspected ADR (sADR) submitted via ADR Reporting app were, complete. The sADR data submitted via ADR reporting app, had an average completeness score of 34.7±2.4 while those submitted via paper based form had an average of 29.2±2.4. The difference is highly significant on Wilcoxon two sample test (p<0.001) and Kolmogorov-Smirnov test (p<0.001).Conclusions: Compared to traditional paper based system, the ADR reporting app based sADR submission, is a better method.

Therapeutic options for patients with Spondyloarthritis (SpA) are limited. The present-day pharmacotherapy for Spondyloarthritis comprises immunomodulator/suppressive drugs. In this case report, we describe a 29-year old Postgraduate resident in Medicine who was diagnosed with spondyloarthritis and was managed by a combination of various disease-modifying drugs like methotrexate and sulfasalazine and immunomodulators such as systemic corticosteroids as well as Tumor Necrosis Factor-alfa inhibitors. After a series of therapeutic trials with them, the chimeric TNF blocker Infliximab led to significant clinical improvement in symptoms and reduction in disease activity.

No abstract